FDA panel backs bronchodilator combo for COPD, with precautions

The FDA usually follows the recommendations of its advisory panels. Panelists have been cleared of potential conflicts of interest related to the topic of the meeting. Occasionally, a panelist may be given a waiver, but that was unnecessary at this meeting.

emechcatie@frontlinemedcom.com